Atopic Dermatitis News and Research

RSS

Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.

Eight-year study identifies potential new way to treat extreme childhood food allergy

An eight-year hunt for the cells that drive the extreme childhood food allergy eosinophilic esophagitis has identified a potential new way to treat the disease while also raising questions about a dietary supplement often taken to reduce bowel inflammation.

9 Apr 2019

Study suggests potential new approach to treat atopic dermatitis

How does the immune system respond to fungi on our skin? Researchers at the University of Zurich have demonstrated that the same immune cells that protect us against skin fungi also encourage the inflammatory symptoms of atopic dermatitis. An antibody therapy could alleviate this chronic inflammatory skin disease.

18 Mar 2019

Higher rates of anxiety and depression found among patients with atopic dermatitis

A British Journal of Dermatology study has found substantially higher rates of anxiety and depression among US adults with atopic dermatitis, compared to those without. The study also found that anxiety and depression often go undiagnosed in these individuals.

6 Mar 2019

Scientists demonstrate key role of salt in allergic immune reactions

Salt apparently affects allergic immune reactions. A team working with Prof. Christina Zielinski at the Technical University of Munich has demonstrated in cell cultures that salt leads to the formation of Th2 cells.

21 Feb 2019

Researchers identify comprehensive guidelines for managing severe atopic dermatitis

A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD), the most common form of eczema.

16 Jan 2019

Investigational topical cream may be effective for treating atopic dermatitis

A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream may be effective for treating atopic dermatitis, one of the most common inflammatory skin diseases.

9 Jan 2019

Dermatology providers show interest in recommending cannabinoids to patients

The cannabis plant and its derivatives have been used in medicinal treatments for millennia. With the recent legalization of medical marijuana in 33 states across the country, as well as Washington, D.C., several specialties are weighing the possibilities of integrating cannabinoids into patient therapies, including dermatology.

11 Dec 2018

Surprising discovery about BH4 may rekindle interest in once-promising pathway

In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, PhD, and chemist Kai Johnsson, PhD, his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief.

19 Nov 2018

Atopic dermatitis found to be highly prevalent among adults in the U.S.

As many as 16.5 million adults in America suffer from a skin disease known as atopic dermatitis, an inflammatory disease that results in red, itchy skin.

30 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Online and in-person care found to be equally effective at improving psoriasis symptoms

For approximately 8 million Americans, visiting a doctor regularly is the key to managing their psoriasis, a chronic inflammatory skin condition characterized by itchy or painful red patches that can appear anywhere on the body.

7 Oct 2018

Robert Koch Institute publishes new data on allergies, mental health problems, and accident injuries

The Robert Koch Institute has published new data from the German Health Interview and Examination Survey for Children and Adolescents on allergies, mental health problems and accident injuries.

19 Sep 2018

New article shines light on shared decision-making between allergists and patients

If you and your doctor chat for a few minutes about treatment options for your allergy symptoms, is that considered shared decision-making (SDM)? It is not, according to a new article published in Annals of Allergy, Asthma and Immunology, the scientific publication of the American College of Allergy, Asthma and Immunology.

7 Sep 2018

Atopic Dermatitis News and Research

Further Reading

Eight-year study identifies potential new way to treat extreme childhood food allergy

Study suggests potential new approach to treat atopic dermatitis

Higher rates of anxiety and depression found among patients with atopic dermatitis

Scientists demonstrate key role of salt in allergic immune reactions

Researchers identify comprehensive guidelines for managing severe atopic dermatitis

Investigational topical cream may be effective for treating atopic dermatitis

Dermatology providers show interest in recommending cannabinoids to patients

Surprising discovery about BH4 may rekindle interest in once-promising pathway

Atopic dermatitis found to be highly prevalent among adults in the U.S.

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Online and in-person care found to be equally effective at improving psoriasis symptoms

Robert Koch Institute publishes new data on allergies, mental health problems, and accident injuries

New article shines light on shared decision-making between allergists and patients

Bee venom may be effective treatment for eczema

Changes in TRPV3 genes may have helped mammoths withstand lower temperatures

Burdensome symptoms of eczema can lead to impaired quality of life, shows study

Seeing the Unexpected: Regulatory T Cells and Basophils

Children with pre-existing allergies should be screened for eosinophilic esophagitis

Researchers uncover racial differences in debilitating itchy skin condition

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News